Expression of immune checkpoints on circulating tumor cells in men with metastatic prostate cancer.
Expression of immune checkpoints on circulating tumor cells in men with metastatic prostate cancer.
复制标题
DOI：
10.1186/s40364-021-00267-y
复制
发表时间：
2021-02-18
影响因子：
11.1
通讯作者：
Armstrong AJ
中科院分区：
文献类型：
--
作者：
Zhang T;Agarwal A;Almquist RG;Runyambo D;Park S;Bronson E;Boominathan R;Rao C;Anand M;Oyekunle T;Healy P;McNamara MA;Ware K;Somarelli JA;George DJ;Armstrong AJ
A subset of men with metastatic prostate cancer (mPC) responds to immune checkpoint inhibitors, and there is an unmet need to predict those most likely to benefit. We characterized circulating tumor cells (CTCs) for expression of immune checkpoint ligands in men with mPC as a non-invasive biomarker of immune evasion and immunotherapy benefit. Three cohorts of patients were enrolled: 1) men with mCRPC starting abiraterone acetate/prednisone or enzalutamide (pre-ARSI), 2) men with mCRPC who were progressing on enzalutamide or abiraterone acetate/prednisone (post-ARSI), and 3) men with newly diagnosed metastatic hormone sensitive prostate cancer (mHSPC) starting androgen deprivation therapy. CTCs were captured using the CellSearch® system and stained for PD-L1, PD-L2, B7-H3, and CTLA-4 at baseline, on treatment, and disease progression. Summary statistics on mean CTCs per cohort, as well as rates of ligand positivity were used to analyze CTCs by cohort and by timepoint. Men in all cohorts and timepoints had prevalent CTC B7-H3 expression (> 80%). We found evidence for CTC PD-L1 expression across disease states, in which > 1 positive CTC or > 50% of CTCs were positive for PD-L1 in 40 and 30% of men with mHSPC, respectively, 60 and 20% of men with mCRPC pre-ARSI, and 70 and 30% of men with mCRPC post-ARSI. CTC PD-L2 expression was present in 20–40% of men in each disease state, while CTC CTLA-4 expression was rare, present in 20% of men with mCRPC pre-ARSI and 10% of men with mCRPC post-ARSI or with mHSPC. CTC immune checkpoint expression was heterogeneous within/between men and across disease states. We have identified that CTCs from men with mPC heterogeneously express immune checkpoints B7-H3, PD-L1, PD-L2, and CTLA-4, and the detection of these immune checkpoints may enable monitoring on immunotherapy. The online version contains supplementary material available at 10.1186/s40364-021-00267-y.
登录
查看更多内容
DOI：
10.1056/nejmoa1315815
发表时间：
2014-09-11
期刊：
The New England journal of medicine
影响因子：
--
作者：
Antonarakis ES;Lu C;Wang H;Luber B;Nakazawa M;Roeser JC;Chen Y;Mohammad TA;Chen Y;Fedor HL;Lotan TL;Zheng Q;De Marzo AM;Isaacs JT;Isaacs WB;Nadal R;Paller CJ;Denmeade SR;Carducci MA;Eisenberger MA;Luo J
通讯作者：
Luo J
影响因子：
6.6
作者：
Mazel, Martine;Jacot, William;Alix-Panabieres, Catherine
通讯作者：
Alix-Panabieres, Catherine
影响因子：
11.5
作者：
de Bono, Johann S.;Scher, Howard I.;Raghavan, Derek
通讯作者：
Raghavan, Derek
影响因子：
45.3
作者：
Beer, Tomasz M.;Kwon, Eugene D.;Gerritsen, Winald
通讯作者：
Gerritsen, Winald
影响因子：
11.2
作者：
Marusyk, Andriy;Polyak, Kornelia
通讯作者：
Polyak, Kornelia